Cargando…

PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?

Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilboudo, Adeodat, Chouhan, Jyoti, McNeil, Brian K., Osborne, Joseph R., Ogunwobi, Olorunseun O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730403/
https://www.ncbi.nlm.nih.gov/pubmed/26703666
http://dx.doi.org/10.3390/ijerph13010012
_version_ 1782412392230027264
author Ilboudo, Adeodat
Chouhan, Jyoti
McNeil, Brian K.
Osborne, Joseph R.
Ogunwobi, Olorunseun O.
author_facet Ilboudo, Adeodat
Chouhan, Jyoti
McNeil, Brian K.
Osborne, Joseph R.
Ogunwobi, Olorunseun O.
author_sort Ilboudo, Adeodat
collection PubMed
description Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA.
format Online
Article
Text
id pubmed-4730403
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47304032016-02-11 PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? Ilboudo, Adeodat Chouhan, Jyoti McNeil, Brian K. Osborne, Joseph R. Ogunwobi, Olorunseun O. Int J Environ Res Public Health Article Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA. MDPI 2015-12-22 2016-01 /pmc/articles/PMC4730403/ /pubmed/26703666 http://dx.doi.org/10.3390/ijerph13010012 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ilboudo, Adeodat
Chouhan, Jyoti
McNeil, Brian K.
Osborne, Joseph R.
Ogunwobi, Olorunseun O.
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title_full PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title_fullStr PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title_full_unstemmed PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title_short PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
title_sort pvt1 exon 9: a potential biomarker of aggressive prostate cancer?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730403/
https://www.ncbi.nlm.nih.gov/pubmed/26703666
http://dx.doi.org/10.3390/ijerph13010012
work_keys_str_mv AT ilboudoadeodat pvt1exon9apotentialbiomarkerofaggressiveprostatecancer
AT chouhanjyoti pvt1exon9apotentialbiomarkerofaggressiveprostatecancer
AT mcneilbriank pvt1exon9apotentialbiomarkerofaggressiveprostatecancer
AT osbornejosephr pvt1exon9apotentialbiomarkerofaggressiveprostatecancer
AT ogunwobiolorunseuno pvt1exon9apotentialbiomarkerofaggressiveprostatecancer